Optimizing GLP-1/GIP Dual Agonism for Enhanced Weight Loss & Metabolic Control to Deliver Superior Patient Outcome

Time: 9:00 am
day: Day One

Details:

• Leveraging co-agonist mechanisms for synergistic receptor activation to maximize therapeutic efficacy for profound and sustained weight reduction
• Characterizing differential receptor potency for tailored pharmacological profiles to improve tolerability for broader patient applicability
• Leveraging large-scale clinical evidence to demonstrate comprehensive metabolic benefits, which establishes new standards of care for transformative patient outcomes

Speakers:

Martin Marro Martin Marro, based in Boston, MA, US, is currently a Executive Director - Cell Pharmacology, Obesity and Complications at Eli Lilly and Company. Martin Marro Read more